NCT04032860View on ClinicalTrials.gov

RCT of Different Effects of Nucleot(s)Ide Analogues on the Prognosis of HBV-HCC Patients After Curative Resection

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

July 1, 2022

Study Completion Date

July 1, 2026

Conditions
HCCHBV Coinfection
Interventions
DRUG

Tenofovir Disoproxil

patients with HBV-HCC would take TDF as antiviral therapy before curative treatment to see the prognosis after surgery

DRUG

Entecavir

patients with HBV-HCC would take ETV as antiviral therapy before curative treatment to see the prognosis after surgery

Trial Locations (1)

610000

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
lead

West China Hospital

OTHER